Manitol Hztm

Mannitol, the active ingredient in Manitol Hztm, is an osmotic diuretic presented as an intravenous solution for intravenous use. It is employed to lower intracranial and intraocular pressure and to promote diuresis in acute renal failure with oliguria. GNH USA supplies Manitol Hztm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manitol Hztm is an osmotic diuretic used in conditions where fluid removal or pressure reduction is required. - Reduction of intracranial pressure: helps lower brain swelling and pressure after trauma or surgery. - Acute renal failure with oliguria: increases urine output to support kidney function. - Reduction of intraocular pressure: assists in managing acute glaucoma or ocular hypertension.

Mannitol may cause a range of adverse reactions, from mild to severe, depending on patient factors and dosing.

Common Side Effects: - Headache - Nausea - Vomiting - Transient hypotension - Electrolyte imbalance (e.g., hyponatremia)

Serious or Rare Side Effects: - Pulmonary edema - Severe electrolyte disturbances such as hypernatremia or hyperkalemia - Acute renal failure exacerbation - Anaphylactic or severe hypersensitivity reaction

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor key parameters. - Renal function: assess baseline renal status and adjust use accordingly. - Electrolyte monitoring: regularly check serum sodium, potassium, and osmolality. - Cardiovascular status: use cautiously in patients with heart failure or compromised circulation. - Fluid balance: avoid excessive volume overload during infusion. - Pregnancy and lactation: use only if potential benefits justify potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mannitol can interact with several drug classes, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Loop diuretics: may cause additive diuresis leading to severe dehydration. - Insulin: mannitol can interfere with glucose control, increasing risk of hyperglycemia. - Nephrotoxic agents: concurrent use may heighten risk of renal injury.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure and renal function for additive effects. - Antihypertensives: may enhance hypotensive response. - Lithium: risk of altered lithium levels; monitor serum concentrations.